S 37435Alternative Names: Growth hormone secretagogues research programme - Kaken; Research programme: growth hormone secretagogues - Kaken
Latest Information Update: 16 Jul 2016
At a glance
- Originator Kaken Pharmaceutical
- Mechanism of Action Growth hormone releasing factor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Dwarfism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dwarfism in Japan
- 07 May 2002 S 37435 is the lead compound of the programme
- 30 May 2001 Preclinical development for Dwarfism in Japan (Unknown route)